Original Paper: Gastrointestinal Oncology
Screening of First Degree Relatives of Patients Operated for Colorectal Cancer: Evaluation of Fecal Calprotectin vs. Hemoccult IIKristinsson J.a · Nygaard K.a · Aadland E.b · Barstad S.c · Sauar J.d · Hofstad B.g · Stray N.h · Stallemo A.f · Haug B.e · Ugstad M.i · Tøn H.i · Fuglerud P.k
Departments of aSurgery and bMedicine, Aker University Hospital, Oslo, Departments of Medicine, the Central Hospitals of cRogaland, dTelemark, eEast Agder, fWest Agder and of gUllevaal University Hospital and hDeacon Hospital, Oslo, iNycomed Pharma AS, Oslo and kVerum Medstat Research AS, Lillestrøm, Norway
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Fecal calprotectin (CPT) is elevated in the majority of patients with known colorectal cancer (CRC), but the specificity is not clarified. Aim: To evaluate if a CPT test (PhiCal ELISA) was more sensitive than Hemoccult II test in detecting colorectal neoplasia, and to obtain reference values in subjects with normal colonoscopy. To evaluate a possible relation between number and extent of dysplasia of adenomas in first degree relatives of patients with CRC and the stage of the carcinoma in the index casus. Further to study the prevalence of CRC and adenomas in the first degree relatives of patients operated for CRC. Method: In a multicenter study, 253 first degree relatives of patients with CRC, aged 50–75 years (mean age 60 years) underwent colonoscopy after having delivered stool samples and three Hemoccult II slides. Results: In 237 first degree relatives from 148 patients with CRC, polyps were found in 118 (50%). Seventy three (31%) had adenomas and 17 had adenomas ≧10 mm. Five had asymptomatic cancers. The specificity of fecal CPT for adenomas at cut off levels ≤10, ≤15 and ≤20 mg/l were 47.4, 59.6 and 71.1%, respectively (max of three samples). The sensitivity at same cut off levels was 56.2, 45.2 and 31.5% and 4/5 of patients with carcinoma had CPT values >15 mg/l. The sensitivity of Hemoccult II for adenomas was 8%, and 4/5 of patients with carcinoma had negative Hemoccult II. The specificity for adenomas was 95%. Conclusion: Fecal CPT test was more sensitive than Hemoccult II in detecting colorectal neoplasia but the specificity was lower. In a high risk group like first degree relatives of patients with CRC, there are good reasons to consider fecal CPT as a first test in selecting patients for endoscopy.
© 2001 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.